These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31613064)

  • 1. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
    Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
    Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
    Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
    Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
    Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
    PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
    Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
    J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
    Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
    Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
    Uchiyama N; Tanaka Y; Kawamoto T
    Eur J Pharmacol; 2017 Oct; 812():138-146. PubMed ID: 28705714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
    Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
    BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of EZH2 alleviates angiogenesis in a model of corneal neovascularization by blocking FoxO3a-mediated oxidative stress.
    Wan SS; Pan YM; Yang WJ; Rao ZQ; Yang YN
    FASEB J; 2020 Aug; 34(8):10168-10181. PubMed ID: 32562311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
    Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
    Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.
    Chiba T; Suzuki E; Negishi M; Saraya A; Miyagi S; Konuma T; Tanaka S; Tada M; Kanai F; Imazeki F; Iwama A; Yokosuka O
    Int J Cancer; 2012 Jun; 130(11):2557-67. PubMed ID: 21717453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting enhancer of zeste homolog 2 protects against acute kidney injury.
    Zhou X; Zang X; Guan Y; Tolbert T; Zhao TC; Bayliss G; Zhuang S
    Cell Death Dis; 2018 Oct; 9(11):1067. PubMed ID: 30341286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.